Arcutis Biotherapeutics (ARQT) insider sale notice: 10,000 shares

Rhea-AI Filing Summary

Arcutis Biotherapeutics, Inc. reporting a Form 144 sale notification for 10,000 common shares to be sold on 03/02/2026 on NASDAQ. The filing notes prior sales by Howard Welgus of 10,000 shares on 01/02/2026 for $289,606.03 and 10,000 shares on 02/02/2026 for $250,482.69.

Insights

Insider Transactions Analyst

Routine Form 144 sale notice showing recent insider dispositions.

The filing lists a planned sale of 10,000 common shares on 03/02/2026 and documents recent disposals by Howard Welgus of 10,000 shares on 01/02/2026 for $289,606.03 and 10,000 shares on 02/02/2026 for $250,482.69. The record also references a stock option exercise dated 06/04/2018.

These entries are administrative sale notices under Form 144; cash proceeds were recorded for the prior transactions. Timing and method for the planned sale are tied to the stated sale date; further transaction details will appear in subsequent filings if executed.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Merrill 8890 Lyra Dr 5th Floor Columbus OH 43215	10000	256517.5	122492192	03/02/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/04/2018	Stock option exercise	Arcutis Biotherapeutics Inc			10000	06/04/2018	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	01/02/2026	10000	289606.03
Howard Welgus 3027 Townsgate Rd Ste 300 Westlake Village CA 91361	Common	02/02/2026	10000	250482.69

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does ARQT's Form 144 disclose about planned sales?

The filing discloses a planned sale of 10,000 common shares scheduled for 03/02/2026. It serves as a notice of an intended disposition under Section 16 rules.

Who sold ARQT shares in the past three months and for how much?

Howard Welgus sold 10,000 shares on 01/02/2026 for $289,606.03 and 10,000 shares on 02/02/2026 for $250,482.69. These amounts are stated in the filing.

Are the proceeds from prior ARQT sales shown in the filing?

Yes; the filing lists proceeds of $289,606.03 for the 01/02/2026 sale and $250,482.69 for the 02/02/2026 sale by Howard Welgus.

Does the Form 144 indicate how the planned sale will be executed?

The filing records the intended sale date 03/02/2026 and listing NASDAQ, but execution method details are not provided in the excerpt.

Is there any mention of option activity in the Form 144?

Yes; the document references a stock option exercise dated 06/04/2018 tied to the common shares reported in the filing.